Gelesis Announces Positive Safety Data from First-In-Human Study of Second Product Candidate, Gelesis200
Juggernaut Announces Strategic Investment by Crescat Capital Funds for 28.95% Ownership - Dr. Quinton Hennigh Technical Advisor